Literature DB >> 17329348

Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice.

Conrad C Weihl1, Sara E Miller, Phyllis I Hanson, Alan Pestronk.   

Abstract

Mutations in p97/VCP cause the autosomal-dominant, inherited syndrome inclusion body myopathy (IBM) associated with Paget's disease of the bone and frontotemporal dementia (IBMPFD) (Watts, G.D., Wymer, J., Kovach, M.J., Mehta, S.G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M.P. and Kimonis, V.E. (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. p97/VCP is a multi-functional protein with a role in the ubiquitin-proteasome system (UPS) (Wang, Q., Song, C. and Li, C.C. (2004) Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. To understand how mutations in this protein lead to a myopathy, we generated several lines of transgenic mice expressing p97/VCP-WT (TgVCP-WT) or the most common IBMPFD mutant, p97/VCP R155H (TgVCP-RH), under a muscle-specific promoter. TgVCP-RH animals, but not controls, became progressively weaker in a dose-dependent manner starting at 6 months of age. Abnormal muscle pathology, which included coarse internal architecture, vacuolation and disorganized membrane morphology with reduced caveolin-3 expression at the sarcolemma developed coincident with the onset of weakness. These changes were not associated with alterations in sarcolemmal integrity as measured by muscle fiber uptake of Evan's blue dye. Even before animals displayed measurable weakness, there was an increase in ubiquitin-containing protein inclusions and high-molecular-weight ubiquitinated proteins, markers of UPS dysfunction. We suggest that this early and persistent increase in ubiquitinated proteins induced by IBMPFD mutations in p97/VCP may ultimately lead to animal weakness and the observed muscle pathology. TgVCP-RH animals will be a valuable tool for understanding the pathogenesis of IBM and the role of the UPS in skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329348     DOI: 10.1093/hmg/ddm037

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  59 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Global gene profiling of VCP-associated inclusion body myopathy.

Authors:  Angèle Nalbandian; Svetlana Ghimbovschi; Shlomit Radom-Aizik; Eric Dec; Jouni Vesa; Barbara Martin; Susan Knoblach; Charles Smith; Eric Hoffman; Virginia E Kimonis
Journal:  Clin Transl Sci       Date:  2012-04-04       Impact factor: 4.689

3.  In vitro studies in VCP-associated multisystem proteinopathy suggest altered mitochondrial bioenergetics.

Authors:  Angèle Nalbandian; Katrina J Llewellyn; Arianna Gomez; Naomi Walker; Hailing Su; Andrew Dunnigan; Marilyn Chwa; Jouni Vesa; M C Kenney; Virginia E Kimonis
Journal:  Mitochondrion       Date:  2015-02-25       Impact factor: 4.160

Review 4.  FTD and ALS--translating mouse studies into clinical trials.

Authors:  Lars M Ittner; Glenda M Halliday; Jillian J Kril; Jürgen Götz; John R Hodges; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2015-05-05       Impact factor: 42.937

Review 5.  Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis.

Authors:  C C Weihl
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

6.  The requirement for Cdc48/p97 in nuclear protein quality control degradation depends on the substrate and correlates with substrate insolubility.

Authors:  Pamela S Gallagher; Sarah V Clowes Candadai; Richard G Gardner
Journal:  J Cell Sci       Date:  2014-02-25       Impact factor: 5.285

7.  mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy.

Authors:  James K Ching; Sarita V Elizabeth; Jeong-Sun Ju; Caleb Lusk; Sara K Pittman; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

8.  VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations.

Authors:  Nam Chul Kim; Emilie Tresse; Regina-Maria Kolaitis; Amandine Molliex; Ruth E Thomas; Nael H Alami; Bo Wang; Aashish Joshi; Rebecca B Smith; Gillian P Ritson; Brett J Winborn; Jennifer Moore; Joo-Yong Lee; Tso-Pang Yao; Leo Pallanck; Mondira Kundu; J Paul Taylor
Journal:  Neuron       Date:  2013-03-14       Impact factor: 17.173

9.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20

10.  Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease.

Authors:  Jeong-Sun Ju; Rodrigo A Fuentealba; Sara E Miller; Erin Jackson; David Piwnica-Worms; Robert H Baloh; Conrad C Weihl
Journal:  J Cell Biol       Date:  2009-12-14       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.